Journals / Dicle Tıp Dergisi / 2017 / Cilt: 44 - Sayı: 3

INH Resistance Mechanisms

INH Direnç Mekanizmaları

Pages
287–292
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This review article discusses the mechanisms of action of INH and the molecular basis of drug resistance in M. tuberculosis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Although the precise mechanism of isoniazid (INH) action on Mycobacterium tuberculosis remains poorly understood, the pro-drug INH enters the cytoplasm through simple passive diffusion.
📊
Key Findings & Data:More than 50% of isoniazid-resistant clinical isolates contain a mutation in KatG wherein the serine at position 315 is substituted with threonine.
💡
Conclusion & Impact:This review article discusses the mechanisms of action of INH and the molecular basis of drug resistance in M. tuberculosis.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Although the precise mechanism of isoniazid (INH) action on Mycobacterium tuberculosis remains poorly understood, the pro-drug INH enters the cytoplasm through simple passive diffusion. It activated by the enzyme catalase/peroxidase encoded by KatG gene. Activation of INH results in the formation of various potent free radical species that are capable of disabling many cellular processes such as mycolic acid synthesis. Mutations in katG are the major mechanism of INH resistance. More than 50% of isoniazid-resistant clinical isolates contain a mutation in KatG wherein the serine at position 315 is substituted with threonine. Several other genes such as inhA, ndh, and efflux pump genes may contribute to INH resistance. This review article discusses the mechanisms of action of INH and the molecular basis of drug resistance in M. tuberculosis.

Özet

Her ne kadar izoniazid (INH) 'ın Mycobacterium tuberculosis üzerindeki etki mekanizması tam anlaşılamamış olsa da öncü ilaç olan INH sitoplazmaya pasif difüzyon ile girmektedir. KatG geni tarafından kodlanan katalaz/peroksidaz enzimi ile aktiflenmektedir. INH 'ın aktiflenmesi ile serbest metabolik radikaller oluşmakta, bunlar da mikolik asit sentezi gibi pek çok hücresel fonksiyonu bozmaktadırlar. KatG mutasyonları INH direncinin ana sebebidir. INH 'a dirençli klinik izolatların % 50 'den fazlasında katG 315. pozisyonda serin yerine treonin 'in değiştiği bir mutasyon vardır. İnhA, ndh ve pompa genleri gibi genler de INH direncine katkıda bulunabilirler. Bu derleme yazısı Mycobacterium tuberculosis 'de INH etki mekanizmasını ve ilaç direncinin moleküler temellerini özetlemektedir.

🔖

Cite This Article

GÖNLÜGÜR, T., GÖNLÜGÜR, U. (2017). INH Resistance Mechanisms. Dicle Tıp Dergisi, Cilt: 44 - Sayı: 3, 287–292. https://ajindex.com/articles/348827

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Unissa AN, Subbian S, Hanna LE, Selvakumar N. Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis. Infect Genet Evol. 2016; 45:474-92
  2. Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis. 1998; 79:3- 29
  3. Heym B, Saint-Joanis B, Cole ST. The molecular basis of isoniazid resistance in Mycobacterium tuberculosis. Tuber Lung Dis. 1999; 79:267-71
  4. Nasiri MJ, Haeili M, Ghazi M, et al. New Insights in to the Intrinsic and Acquired Drug Resistance Mechanisms in Mycobacteria. Front Microbiol. 2017; 8:681
  5. Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis: update 2015. Int J Tuberc Lung Dis. 2015; 19:1276-89
  6. Timmins GS, Deretic V. Mechanisms of action of isoniazid. Mol Microbiol. 2006; 62:1220-7
  7. Musser JM. Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin Microbiol Rev. 1995; 8:496-514
  8. Cohn ML, Kovitz C, Oda U, Middlebrook G. Studies on isoniazid and tubercle bacilli. II. The growth requirements, catalase activities, and pathogenic properties of isoniazid-resistant mutants. Am Rev Tuberc. 1954; 70:641-64
  9. Almeida Da Silva PE, Palomino JC. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. J Antimicrob Chemother. 2011; 66:1417-30
  10. Cade CE, Dlouhy AC, Medzihradszky KF, et al. Isoniazid-resistance conferring mutations in Mycobacterium tuberculosis KatG: catalase, peroxidase, and INH-NADH adduct formation activities. Protein Sci. 2010; 19:458-74
  11. Rahim Z, Nakajima C, Raqib R, Zaman K, Endtz HP, van der Zanden AG, Suzuki Y. Molecular mechanism of rifampicin and isoniazid resistance in Mycobacterium tuberculosis from Bangladesh. Tuberculosis (Edinb). 2012; 92:529-34
  12. Aslan G, Tezcan S, Serin MS, Emekdas G. Genotypic analysis of isoniazid and rifampin resistance in drugresistant clinical Mycobacterium tuberculosis complex isolates in southern Turkey. Jpn J Infect Dis. 2008; 61:255-60
  13. Barry CE 3rd, Slayden RA, Mdluli K. Mechanisms of isoniazid resistance in Mycobacterium tuberculosis. Drug Resist Updat. 1998;1: 128-34
  14. Slayden RA, Barry CE 3rd. The genetics and biochemistry of isoniazid resistance in mycobacterium tuberculosis. Microbes Infect. 2000;2: 659-69
  15. Pinheiro M, Silva AS, Pisco S, Reis S. Interactions of isoniazid with membrane models: implications for drug mechanism of actio